NCT04324151招募中不适用
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2020年3月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
详细描述
Inclusion criteria:
diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- •Potentially Resectable NSCLC
- •Treatment Plan is Crizotinb or Standard Chemotherapy
排除标准
- •Patients with contraindication of chemotherapy
- •Pregnant or breast feeding women
结局指标
主要结局
PFS
时间窗: may 2020- may 2021 (1 year)
Progression free survival
次要结局
- ORR(may 2020- may 2021 (1 year))
- OS(may 2020- may 2021 (1 year))
研究者
Yongchang Zhang
professor
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Non Small Cell Lung CancerImmune Checkpoint InhibitorEGFR Exon 21 MutationNCT06142617Peking Union Medical College Hospital37
招募中
2 期
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous CellNeoadjuventPD-1 InhibitorChemotherapyEsophageal Squamous Cell CarcinomaNCT06006650Tang-Du Hospital114
进行中（未招募）
2 期
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerLocally Advanced Colorectal CancerLocally Advanced Rectal CancerNCT05585814Shanghai Changzheng Hospital30
招募中
2 期
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT05286619University of Malaya63
撤回
2 期
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)Multiple MyelomaNCT03221634Merck Sharp & Dohme LLC